Clinical Trial Update: Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AZD6094 (Volitinib) in advanced gastric adenocarcinoma with MET amplification as a third-line treatment has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• AZD6094 (Volitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED